Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been imp...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Bhatti, Maria, Ippolito, Thomas, Mavis, Cory, Gu, Juan, Cairo, Mitchell S., Lim, Megan S., Hernandez-Ilizaliturri, Francisco, Barth, Matthew J.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955151/
https://ncbi.nlm.nih.gov/pubmed/29774105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25072
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items